ZNF660 and posterior cortical atrophy: Building on previous evidence that ST6GALNAC3 and ZNF660 methylation may be putative biomarkers of PCa [111], their clinical performance was evaluated in a large and heterogeneous cohort (qMSP; PCa n = 169, precancerous lesions n = 10, BPH n = 13, mPCa n = 15, CRPC n = 7 and adjacent prostate tissues n = 20) [112].